Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allowing CBD Use In Supplements Benefits Drug Innovation – Trade Groups

Executive Summary

Developing rules for using CBD in supplements will prevent pharma industry from creating “sweeping monopoly” over the ingredient, CRN says. CHPA says FDA's existing NDA process is appropriate not only for Rx drugs containing CBD, but also for OTC products. NPA supports allowing an exemption for CBD in supplements by establishing a daily exposure level for a healthy population through a Health Hazard Evaluation.

You may also be interested in...



US Wellness Market In 2019: Farm Bill Made Cultivating Cannabidiol Policy FDA's Main Course In Supplements

As HBW Insight looks back on notable US wellness market developments and events for the previous 12 months, we find that news in the CBD space from the FDA and the industry dominated the sector throughout 2019.

FDA Warns 15 CBD Product Marketers For Violations, Cautions Consumers: CBD May Harm You

The agency announces that it cannot conclude cannabidiol is GRAS, potentially heading off GRAS notifications and making NDI notifications a likelier future for CBD use in the supplement sector if any “lawful pathway” is to be found. In addition to a barrage of warning letters to marketers of CBD products, the FDA issued a stark warning to consumers about potential hazards.

NJ Senators Tell Congress 'Complicated Legal Framework' Hurts CBD Firms

NJ senators say although FDA deems dietary ingredients and food additives with CBD as unlawful, in the past three years more than 1,500 CBD products have come to market “without a clear approach for regulation or any plan from the FDA to balance consumer access and protect consumer health.”

Related Content

Topics

UsernamePublicRestriction

Register

RS149026

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel